Dias André Ivan Bradley dos Santos, Fachin Camila Girardi, Avó Lucimar Retto Silva, Frazão Caio Vinicius Gonçalves, Caran Eliana Maria Monteiro, Schettini Sérgio Tomaz, Alves Maria Teresa Seixas, Ribeiro Raul C, Abib Simone de Campos Vieira
Pediatric Surgery, Department of Surgery, Universidade Federal de São Paulo/ Escola Paulista de Medicina - UNIFESP/EPM, Rua Coronel Lisboa, 687, São Paulo-SP, 04020-041, Brasil.
Pediatric Surgery, Department of Surgery, Universidade Federal de São Paulo/ Escola Paulista de Medicina - UNIFESP/EPM, Rua Coronel Lisboa, 687, São Paulo-SP, 04020-041, Brasil.
J Pediatr Surg. 2015 Aug;50(8):1323-8. doi: 10.1016/j.jpedsurg.2014.12.006. Epub 2014 Dec 18.
BACKGROUND/PURPOSE: Pediatric adrenocortical tumor (ACT) remains a challenging disease. Tumor weight and disease stage are still the most used indicators to prognosis and guidance of clinical decisions. Histology has not added meaningful data for risk stratification and management. ACT is metabolically active, highly vascularized, locally invasive and has the propensity to produce distant metastasis. Our objective was to correlate the expression of vascular endothelial growth factor (VEGF) and intratumoral microvessel density (MVD) with clinical and prognostic aspects in pediatric ACT.
In 27 tumors, immunohistochemical expression of VEGF, CD105 (endoglin) and CD34 was analyzed. MVD was determined by CD34 and CD105 antibodies. MVD and VEGF expression was correlated with clinical characteristics and outcome. Normal pediatric glands were used as controls.
Endoglin MVD was significantly higher and CD34 MVD was significantly lower in ACT than control. The VEGF expression did not differ between groups. Cytoplasmic staining for endoglin was correlated with hypertension in ACT. Endoglin MVD greater than 1 mv/field, CD34 MVD less than 32 mv/field and VEGF expression levels above 4.8% were associated with clinical and biological indicators of poor prognosis.
Endoglin and CD34 MVD values are potential histological markers to refine the histologic classification of pediatric ACT.
背景/目的:小儿肾上腺皮质肿瘤(ACT)仍然是一种具有挑战性的疾病。肿瘤重量和疾病分期仍是用于预后评估及指导临床决策的最常用指标。组织学检查尚未为风险分层和治疗提供有意义的数据。ACT具有代谢活性、血管高度丰富、局部浸润性且易于发生远处转移。我们的目的是探讨血管内皮生长因子(VEGF)的表达及肿瘤内微血管密度(MVD)与小儿ACT临床及预后因素的相关性。
对27例肿瘤进行VEGF、CD105(内皮糖蛋白)和CD34的免疫组化表达分析。采用CD34和CD105抗体测定MVD。将MVD和VEGF表达与临床特征及预后进行相关性分析。以正常小儿肾上腺作为对照。
与对照组相比,ACT中内皮糖蛋白MVD显著升高,CD34 MVD显著降低。两组间VEGF表达无差异。ACT中内皮糖蛋白的细胞质染色与高血压相关。内皮糖蛋白MVD大于1个微血管/视野、CD34 MVD小于32个微血管/视野以及VEGF表达水平高于4.8%与预后不良的临床及生物学指标相关。
内皮糖蛋白和CD34 MVD值是优化小儿ACT组织学分类的潜在组织学标志物。